Allogene Therapeutics (ALLO) Free Cash Flow (2018 - 2026)
Allogene Therapeutics (ALLO) reported Free Cash Flow of -$12.9 million for Q1 2026, up 75.59% on a YoY basis from -$7.4 million in Q1 2025, and up 53.35% sequentially from -$27.7 million in Q4 2025.
Allogene Therapeutics (ALLO) Free Cash Flow (2018 - 2026) Analysis & Trends
Allogene Therapeutics (ALLO) has 9 years of Free Cash Flow data on file, last reported at -$12.9 million in Q1 2026.
- For the quarter ending Q1 2026, Free Cash Flow rose 75.59% year-over-year to -$12.9 million; the trailing twelve-month figure through Mar 2026 stood at -$110.5 million (up 43.17% YoY), and the FY2025 full-year result was -$150.5 million, up 23.2% from the prior year.
- Free Cash Flow improved to -$12.9 million in Q1 2026, from -$27.7 million in the prior quarter.
- In the past five years, Free Cash Flow ranged from a high of -$12.9 million in Q1 2026 to a low of -$70.1 million in Q1 2022.
- A 5-year average of -$48.5 million and a median of -$52.9 million in 2025 frame the typical range for Free Cash Flow.
- Across the five-year window, Free Cash Flow tumbled 42.1% in 2022 and soared 75.59% in 2026, its largest moves.
- Tracing ALLO's Free Cash Flow over 5 years: stood at -$64.1 million in 2022, then grew by 16.0% to -$53.8 million in 2023, then soared by 40.58% to -$32.0 million in 2024, then increased by 13.39% to -$27.7 million in 2025, then soared by 53.35% to -$12.9 million in 2026.
- Business Quant data shows ALLO's Free Cash Flow at -$12.9 million in Q1 2026, -$27.7 million in Q4 2025, and -$30.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -19.58 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 158.09 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -1.53 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.29 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 848.30 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -354.95 Mn |
| 10 | Allogene Therapeutics | 437.33 Mn | 437.33 Mn | - | -12.92 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -12.92 Mn |
| Mar 31, 2026 | -12.92 Mn |
| Dec 31, 2025 | -27.70 Mn |
| Dec 31, 2025 | -27.70 Mn |
| Sep 30, 2025 | -30.66 Mn |
| Sep 30, 2025 | -30.66 Mn |
| Jun 30, 2025 | -39.25 Mn |
| Jun 30, 2025 | -39.25 Mn |
| Mar 31, 2025 | -52.93 Mn |
| Mar 31, 2025 | -52.93 Mn |
| Dec 31, 2024 | -31.98 Mn |
| Dec 31, 2024 | -31.98 Mn |
| Sep 30, 2024 | -44.55 Mn |
| Sep 30, 2024 | -44.55 Mn |
| Jun 30, 2024 | -65.03 Mn |
| Jun 30, 2024 | -65.03 Mn |
| Mar 31, 2024 | -54.45 Mn |
| Mar 31, 2024 | -54.45 Mn |
| Dec 31, 2023 | -53.83 Mn |
| Dec 31, 2023 | -53.83 Mn |